At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Randomized, Crossover Study to Assess Nicotine Uptake, Tobacco-Related Biomarkers of Exposure, Biomarkers of Potential Harm, and Puff Topography With Use of mybluTM Electronic Cigarettes in Adult Smokers
In Brief
A clinical study evaluating Myblu flavor A_2.4, Myblu flavor B_2.4, and 6 other interventions for Healthy Volunteers. Completed, enrolled 39 participants across 1 site.
Detailed Summary
This study evaluates the overall performance of the currently-marketed MybluTM e-cigarette device and pods, as assessed by nicotine uptake, exposure to smoke constituents, safety and consumer satisfaction, over 8 days. The study is designed as an open-label, randomized study in adult smokers. Subjects are invited to participate to a second part of the study, for 5 additional days, to compare the use of MybluTM to the use of subject's usual brand combustible cigarettes.
Study Details
Timeline
Interventions
Use of Myblu e-cigarette with flavor 1 at 2.4% nicotine
Use of Myblu e-cigarette with flavor 2 at 2.4% nicotine
Use of Myblu e-cigarette with flavor C at 2.4% nicotine
Use of Myblu e-cigarette with flavor D at 2.4% nicotine
Use of Myblu e-cigarette with flavor 1 at 1.2% nicotine
Fse of Myblu e-cigarette with flavor F at 1.2% nicotine
Use of Myblu e-cigarette with flavor G at 2.4% nicotine
Use of Myblu e-cigarette with flavor H at 2.4% nicotine